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Abstract: Diverse species of cyanobacteria have recently been discovered to produce the 
neurotoxic non-protein amino acid β-methylamino-L-alanine (BMAA). In Guam, BMAA 
has been studied as a possible environmental toxin in the diets of indigenous Chamorro 
people known to have high levels of Amyotrophic Lateral Sclerosis/ Parkinsonism 
Dementia Complex (ALS/PDC). BMAA has been found to accumulate in brain tissues of 
patients with progressive neurodegenerative illness in North America. In Guam, BMAA 
was found to be produced by endosymbiotic cyanobacteria of the genus Nostoc which live 
in specialized cycad roots. We here report detection of BMAA in laboratory cultures of a 
free-living marine species of Nostoc. We successfully detected BMAA in this marine 
species of Nostoc  with five different methods: HPLC-FD, UPLC-UV, Amino Acid 
Analyzer, LC/MS, and Triple Quadrupole LC/MS/MS. This consensus of five different 
analytical methods unequivocally demonstrates the presence of BMAA in this marine 
cyanobacterium. Since protein-associated BMAA can accumulate in increasing levels 
within food chains, it is possible that biomagnification of BMAA could occur in marine 
ecosystems similar to the biomagnification of BMAA in terrestrial ecosystems. Production 
of BMAA by marine cyanobacteria may represent another route of human exposure to 
BMAA.  Since BMAA at low concentrations causes the death of motor neurons, low levels 
of BMAA exposure may trigger motor neuron disease in genetically vulnerable 
individuals. 
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1. Introduction  
 
Cyanobacteria produce a variety of toxic compounds known as cyanotoxins [1]. Human health 
consequences of cyanotoxins have been of increasing concern as the impacts of cyanobacterial blooms 
in water supplies as well as near-shore marine ecosystems have become better understood [2]. 
Poisonings from cyanobacterial blooms can be catastrophic [3], such as the death of 50 dialysis 
patients following exposure to inadequately treated water from the Tabocas Reservoir in Brazil or the 
hospitalization of 140 children and 10 adults who drank cyanobacterially-contaminated water 
impounded by the Solomon dam in Australia [4, 5]. Cyanobacterial toxins have also been implicated in 
wildlife deaths in fisheries and terrestrial mammals, and can accumulate within the ecosystem. Potent 
hepatotoxins such as cyclic heptapeptides including microcystins, and cyclic pentapeptides including 
nodularins are produced by Anabaena, Microcystis, Oscillatoria, Nostoc, Anabaenopsis, and 
Nodularia  species. Different neurotoxins are known to be produced by cyanobacteria including 
anatoxin-a, homoanatoxin-a, anatoxin-a(S), and saxitoxins from Anabaena,  Aphanizomenon, 
Oscillatoria, Lyngbya, and Cylindrospermopsis [1, 3]. 
We found that endophytic cyanobacteria of the genus Nostoc resident in specialized roots of the 
Guam cycad Cycas micronesica Hill (Cycadaceae) produced a different neurotoxin, β-methylamino-L-
alanine (BMAA), which is found throughout cycad tissues [8, 9]. This led to a broader examination of 
BMAA production by other taxa of cyanobacteria, including 30 laboratory strains of free-living 
cyanobacteria, representing five major microbiological taxonomic groups of Rippka et al. [10]. Of the 
thirty laboratory cultures, 29 had free or protein-bound BMAA, as did a sample of an ocean 
Trichodesmium  bloom [11]. BMAA has also been found in bloom samples of cyanobacterially-
contaminated water supplies in the United Kingdom, where it was found to co-occur with other 
cyanotoxins including microcystins, nodularin, anatoxin-a, and saxitoxins [12].  
The co-occurrence of BMAA with other cyanotoxins may be of ecological importance, since 
BMAA can potentiate injury to motor neurons at concentrations as low as 10 μM [13].  Alone, BMAA 
has been found to selectively kill motor neurons at concentrations as low as 30 μM by AMPA/kainate 
receptor activation [14].  
Figure 1. BMAA. 
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Although BMAA is a glutamate agonist at AMPA and NMDA receptors, it is a structurally 
dissimilar polar amino acid with two functional groups. Also known by the synonyms α-amino-β-
methylaminopropionic acid (MeDAP) and S(+)-m-methyl-α,β-diaminopropionic acid, BMAA has a 
molecular weight of 118.13. Originally isolated from the seeds of cycads, BMAA can be synthesized 
from  α-acetamidoacrylic acid [15, 16]. Its structure is basically that of alanine with an added 
methylated amino group (Figure 1). Historically, BMAA was thought to be a possible slow toxin [17] 
associated with neurodegenerative illness among the Chamorro people of Guam [18]. The interest in 
BMAA has recently been renewed with evidence that BMAA is incorporated into the protein fraction 
of cyanobacteria, cycads, animals that forage on cycad seeds, as well as indigenous people with 
traditional diets rich in BMAA [8, 19]. The incorporation and storage of BMAA in protein explains not 
only how biomagnification of a water-soluble molecule can occur, but also may account for the 
observed disease latency in ALS/PDC due to the intermittent release of the endogenous neurotoxic 
reservoir stored in the proteins [19]. Some forms of progressive neurodegenerative illness are 
associated with protein misfolding and protein truncation—likely occurrences in the case of a foreign 
amino acid insertion during protein synthesis—and could conceivably trigger neurodegeneration. 
 
Figure 2. Fluorescence and differential interference contrast microphotographs of 
lyophilized marine Nostoc sp.  
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The incorporation of BMAA into protein was first demonstrated by Polsky, Nunn and Bell, who 
found BMAA in an extract removed from cycad seeds; acid hydrolysis of the extract released BMAA 
in greater amounts than found in the free fraction [20]. Subsequently, the insertion of BMAA into 
artificial peptides [21] further demonstrated the potential for protein-bound BMAA in natural systems. 
However, association of a non-protein amino acid like BMAA with proteins is not unusual, since there 
are many other cases of unusual amino acids being associated with cyanobacterial proteins [22]. For 
such studies, hydrochloric acid (HCl) hydrolysis is by far the most commonly used method of 
releasing amino acids from proteins [23]. The conventional acidic hydrolysis uses 6N HCl for 18 to 24 
hours in vacuo and provides high recovery of all protein-bound amino acids except tryptophan. 
The detection and quantification of BMAA in a sample increases in difficulty as the concentration 
of BMAA decreases and the complexity of the physiological matrix increases. While it is relatively 
simple to detect the high concentration of BMAA in a cycad seed gametophyte or even a low 
concentration of synthetic BMAA standard with standard chromatographic techniques, detection of 
BMAA in low concentration in a complex physiological matrix (such as in a cyanobacterium, or a 
human brain sample) requires careful method development and validation. Single injection 
experiments, particularly those performed by investigators with little previous amino acid experience 
are unlikely to result in detection. Multiple techniques to confirm the presence of BMAA in a sample 
are preferred. To unequivocally demonstrate that a marine cyanobacterium, a laboratory strain of 
Nostoc sp. known as CMMED-01 (Figure 2), produces BMAA, we used five different techniques to 
assay it for the production of BMAA. 
 
2. Results and Discussion 
 
2a. Fluorescence microscopic examination of CCMED-01 
 
   Fluorescence microscopy of the lyophilized marine culture CCMED-01 confirmed that the sample 
was indeed cyanobacterial, while differential interference microscopy confirmed that it was a species 
of the genus Nostoc (Figure 2). The linear "pearls on a string" structure of Nostoc was visible with 
clear heterocysts, and the cyanobacterium fluoresced with excitation at 550 nm and emission at 590 
nm.  However, since proportion of specific pigments may change during Nostoc lifecycles, emission 
wavelengths may also change [24].  
 
2b. Chromatographic and Spectrometric Determination of BMAA in CCMED-01 
 
All five of the different techniques we employed confirmed the presence of BMAA in lyophilized 
samples of the marine Nostoc strain, CMMED-01. High performance liquid chromatography with 
fluorescence detection (HPLC-FD) detected BMAA as a free amino acid (7 μg/g) in the marine Nostoc 
samples (Figure 3). The CCMED-01 peak for BMAA is consistent with the BMAA standard. Relative 
to the standard amino acids, BMAA elutes closest to methionine (MET). The HPLC analysis of free 
plus protein-bound BMAA, performed with different gradients, also detected the BMAA peak (Figure 
4).  In this analysis, 10 µg/g of BMAA was found in the Nostoc CMMED-01 sample. 
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Figure 3. HPLC-FD chromatogram of free BMAA in marine Nostoc. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sample spiked with 32 picomoles of BMAA elutes within the time range of the synthetic 
BMAA (Figure 4).  Although the two different HPLC-FD analyses use different gradients, they were 
united by the use of a sodium acetate buffer and fluorescent detection. 
 
Figure 4. HPLC-FD of total BMAA in a marine Nostoc. 
 
 
 
 
 
 
 
    
     
 
 
 
 
 
 
 
 
 
In contrast, during Ultra Performance Liquid Chromatography (UPLC), which operates at much 
higher pressure and uses a formic acid buffer instead of sodium acetate, BMAA elutes closest to Mar. Drugs 2007, 5  185  
 
lysine, and the sequence of amino acids is totally different. The UPLC method with UV detection 
determined the presence of BMAA (25 μg/g) in a CCMED-01 cyanobacterial sample (Figure 5).  
 
Figure 5. BMAA elutes in a different position in UPLC than in HPLC. 
                     
 
 
In both HPLC methods and the UPLC method, precolumn derivatization of the amino acids in the 
sample was performed using the fluorescent tag 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
(AQC). AQC universally tags amino acids at primary and secondary nitrogens producing complex 
molecules that do not degrade during high pressure separation and are stable for a period of up to six 
months of normal storage [25]. Further advantages of the AQC reaction include the increased 
sensitivity over less modern techniques including phenylisothiocyanate (PITC), o-pthalaldehyde 
(OPA) and FMOC derivatizations, and increased efficiency of separation by reverse phase 
chromatography. 
In contrast to the HPLC and UPLC techniques which use precolumn AQC derivatization of the 
cyanobacterial sample, BMAA was also detected with a Hitachi Amino Acid Analyzer (AAA) that 
uses postcolumn derivatization with ninhydrin (Figure 6). Amino acid analyzers are often used in 
hospital settings for analysis of amino acid contents of physiological fluids. In the AAA system, the 
non-protein amino acid BMAA elutes between ammonia and lysine. Once again, the sequence of 
amino acids coming off the column is totally different from the HPLC sequence and the UPLC 
sequence. Since BMAA, relative to other more common amino acids, elutes in a different position in 
the sequence than in HPLC and UPLC, with the use of such multiple techniques, the possibility of 
experimental error due to coelution of BMAA with another molecule can be minimized. 
While the three different  liquid chromatography techniques we employed (HPLC, UPLC, and 
Amino Acid Analyzer) depend on differential retention time of an analyte in a chromatographic 
column as compared to other molecules, mass spectrometry differentiates amino acids by their 
molecular weight. This combination of BMAA detection with HPLC or UPLC coupled with mass Mar. Drugs 2007, 5  186  
 
spectrometric verification of the BMAA peak reconfirms HPLC or UPLC detection of BMAA in a 
sample [8, 11, 12, 19]. 
 
Figure 6. BMAA appears in a different position with an amino acid analyzer than in HPLC or UPLC. 
 
 
We used two different spectrometric techniques to verify the BMAA peak in the CCMED-01 
marine Nostoc sp. samples.  First, we used a Waters EMD-1000 single quadrupole mass spectrometer 
to determine the mass of the peak we identified as BMAA with the UPLC separation. Using a direct 
UPLC injection of the AQC-derivatized sample into a single quadrupole liquid chromatograph/ mass 
spectrometer (LC/MS), BMAA was clearly detected (Figure 7) with a mass of 459 [mw= BMAA (118) 
+ two AQC molecules (mw=170) at the two nitrogen groups + one ion at the LC/MS electrospray 
interface]. 
 
Figure 7. An in-line UPLC/LCMS was used to verify the BMAA peak.
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We also detected BMAA from an LC injection into a triple quadrupole LC/MS/MS. In this case, 
we compared the fragmentation pattern of BMAA in the second quadrupole to that of another amino 
acid, L-2,4-diamino-n-butyric acid, which has a molecular weight of 118.13, equivalent to BMAA, but 
with a different molecular structure. Our triple quadrupole instrument is designed to detect low 
molecular weight molecules in a complex physiological matrix [26]. This instrument has four checks 
to determine that the test molecule is equivalent to the standard: (1) in the first quadrupole, the 
instrument excludes all ions except the specific single parent mass (459 mw) from entering the second 
quadrupole; (2) the retention time of the molecule after interaction with the column is unique; (3) the 
product ions detected in the third quadrupole must all be present following the collision-induced 
dissociation within the second quadrupole; and (4) the ratios of the three product ions (Figure 8) must 
match within ± 5 % variation as compared with repetitive runs of the BMAA standard injected at a 
similar concentration. We used three aliquots from a CMMED-01 sample, and used 17 different runs 
of BMAA standard to estimate experimental variance.   
Our Nostoc sp. sample met all four of these checks for the presence of BMAA: (1) in the first 
quadrupole, ions with a mass of 459 were present; (2) the retention time for the sample was 13.59 min. 
± 0.08  compared to 13.49 min. ± 0.11 for the BMAA standard; (3) the product ions with masses of 
171, 289, and 119 were detected in the third quadrupole for both the sample and the BMAA standard; 
(4) the ratio of the three fragmentation product ions were similar for the sample and the BMAA 
standard (Figures 8, 9). The ratios are normalized by the proportion of the largest daughter ion with a 
mass of 171 (A). The ratios of the product ion with mass of 289 (B) to the daughter ion with mass of 
171 (A) for sample and standard were 25.3 ± 0.97 and 24.4 ± 1.8, respectively; while the ratios for 
product ions with mass of 119 (C) to the daughter ion with mass of 171 (A) were 11.9 ± 0.69 and 12.5 
± 0.3, respectively. 
 
Figure 8.  Product ions from collision-induced dissociation of double-derivatized BMAA 
in LC/MS/MS. 
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Figure 9. Triple quadrupole LC/MS/MS of BMAA in a marine Nostoc sp. 
 
 
3. Conclusions 
 
The use of three different HPLC techniques and two different LC/MS techniques conclusively 
demonstrates that the marine cyanobacterial species represented by Nostoc CCMED-001 produces the 
neurotoxic non-protein amino acid, β-methylamino-L-alanine. The precise fragmentation pattern and 
collision-induced dissociation ion ratios of the LC/MS/MS provide unequivocal evidence of BMAA in 
the sample. Although BMAA is present in the cyanobacterium, we detected some variation in 
concentration since the samples tested were taken at different times from the parent culture. Variation 
in concentration is not unexpected, since nitrogenase activity within marine cyanobacteria can vary 
dramatically within a single day as well as throughout the life cycle depending on the specific taxon, 
photon flux, and culture senescence [27-29]. Our study confirming through five different techniques 
the presence of BMAA in a marine Nostoc species supports the addition of BMAA to the list of 
phycotoxins produced by cyanobacteria [30]. 
Originally discovered in 1967 in cycad seeds from Guam [15, 16], BMAA for 45 years was 
believed to occur only in cycads. As such, the putative link of BMAA to the debilitating paralytic 
disease ALS/PDC suffered by the Chamorro people was believed to be related only to the Chamorro 
consumption of flour made from the seed gametophytes of Cycas micronesica Hill [15-20]. Claims 
that Chamorro processing procedures remove nearly all of the BMAA from cycad flour, combined 
with no clear etiological linkage of cycad consumption in the two other foci of ALS/PDC in West 
Papua and the Kii peninsula of Japan, led to BMAA being discounted as a possible cause of 
neurodegenerative illness among the Chamorro people [18]. Furthermore, there was no conceivable 
connection of BMAA to other forms of progressive neurodegenerative illness in the parts of the world 
where cycads do not occur.  Mar. Drugs 2007, 5  189  
 
Interest in BMAA was rekindled, however, in 2002 when it was hypothesized that BMAA may 
accumulate within animals that eat cycads [32]. Experimental evidence for such bioaccumulation soon 
followed [33, 34].  In 2003, it was discovered that BMAA is produced by cyanobacteria of the genus 
Nostoc which live as symbionts within specialized cycad roots [8]. In 2004 it was discovered that 
BMAA can be bound to proteins, including the proteins of cycad flour which had not been previously 
investigated [19]. Thus a new pictured emerged: BMAA was present within the traditional Chamorro 
diet from multiple sources in far higher concentrations than had previously been suspected [8, 19, 34]. 
In 2005, it was discovered that BMAA can be produced by diverse taxa of cyanobacteria [11]. It was 
thought that this broad pattern of cyanobacterial production of BMAA might provide a clue into why 
BMAA was found in brain tissues of patients with progressive neurodegenerative illness who lived far 
from Guam [19, 35]. 
Confirmation through five different techniques that BMAA is produced by the marine Nostoc 
species represented by the CCMED-01 samples increases our interest in finding out if  this potent 
neurotoxin, which selectively targets motor neurons [13, 14], can be biomagnified within marine 
ecosystems. We await with interest the results of ongoing studies of BMAA biomagnification at the 
University of Hawaii, Stockholm University, Chiba University, and our Institute designed to test this 
possibility. It also would be interesting to know if marine (or even fresh-water) cyanobacteria play a 
role in human exposure to BMAA in the ALS/PDC focus in Kii, Japan. Furthermore, the recent 
finding that BMAA co-occurs with other cyanotoxins in contaminated water supplies raises the 
possibility that low-level human exposure to BMAA may occur in many parts of the world [12]. In 
contrast to ALS/PDC foci, such as Guam, where exposure to high levels of BMAA in traditional diets 
may constitute a broad threat to human health, exposures to low concentrations of BMAA in marine or 
freshwater ecosystems may trigger progressive neurodegenerative illness among genetically vulnerable 
individuals, potentially resulting in a new paradigm for sporadic motor neuron disease [19, 36]. Until 
more is known about the possible link between BMAA and gene/environment interactions in 
progressive neurodegenerative illnesses, we again suggest [11] that it is now prudent to begin to 
assemble baseline data on the presence of BMAA in water supplies and human diets. 
 
4.  Experimental  
 
General 
 
   The marine Nostoc sp. culture CMMED-01 was based on a sample originally collected on June 2, 
2004 in Kaneohe Bay, on the island of Oahu in Hawaii by D. Hashimoto and identified by B. 
Anderson. This collection was cultured and maintained by R. Bidigare, G, Tien and colleagues at The 
Center for Marine Microbial Ecology and Diversity at the University of Hawaii, Manoa and sent to our 
laboratory by S. Christensen and A. Messner. 
 
4a. Fluorescence microscopy 
 
The lyophilized marine Nostoc sp. culture was reconstituted in water, and fresh mounted or   
mounted with Permount SP15-100 Toluene solution (Fisher Scientific, Fair Lawn, NJ) on microscope Mar. Drugs 2007, 5  190  
 
slides. The cyanobacteria were imaged with a Zeiss Axioplan 2 microscope. The cyanobacteria were 
examined with differential interference contrast and fluorescence microscopy with excitation at 550 
nm and emission at 590 nm using a Chroma filter set (Chroma Technology, Rockingham, VT).  
 
4 b1. Fluorescence HPLC methods for analysis of free-BMAA  
 
Freeze-dried cyanobacterial samples were macerated in liquid nitrogen, weighed, hand macerated 
in trichloroacetic acid (0.4 mg/mL 0.1N TCA), vortexed, and extracted for 12 h at 4°C.  Samples were 
centrifuged and the supernatant decanted. The pellet was remacerated in TCA (50 μL), vortexed, and 
re-extracted for 1 h at room temperature. Samples were centrifuged and the TCA supernatants pooled 
and filtered (0.22 μm Ultrafree-MC, Millipore) at 13,800 g for 5 min (Labnet Spectrafuge 16M).  Free 
amino acid extracts were derivatized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC 
Waters AccQTag reagent, PN WAT052880) following standardized, validated protocols: sample (20 
μL) was buffered with 0.5 M borate (80 μL) and derivatized with AQC (20 μL) [9].  Sample batches 
for analysis included derivatized samples, blanks [20 mM HCl (20 μL with 0.5 M borate (80 μL) and 
derivatized with AQC (20 μL)], derivatized 17 amino acid standard complex (Pierce #NCI0180, 
Rockford, IL) spiked with BMAA to assure adequate separation, derivatized BMAA standard for 
quantification, water blanks, and derivatized low-level spiked samples for peak identification and to 
check for a balanced reaction. BMAA was separated from other amino acids by reverse-phase elution 
(Waters Nova-Pak C18 column, 3.9 x 300 mm) on a Waters 1525 binary HPLC pump and a Waters 
717 Autosampler using a gradient method with 140 mM sodium acetate, 5.6 mM triethylamine, pH 5.2 
(Eluent A), and 52% acetonitrile in water (Eluent B) at 37°C, a flow rate of 1.0 mL/min, and a 10 μL 
sample injection. The standard amino acid elution gradient was modified for BMAA separation on a 
60 min gradient (0.0 min = 100% A; 2 min = 90% A curve 11; 5 min = 84% A curve 11; 10 min = 84 
% A curve 6; 18 min = 75% A curve 6; 33 min = 65% A curve 10; 35 min = 40% A curve 6; 37.5 min 
= 100% B curve 6; 47 min = 100% B curve 6; 50 min =100% A curve 6; 60 min =100% A curve 6). 
BMAA concentration was quantified by detection of the fluorescent tag (Waters 2475 Multi λ-
Fluorescence Detector) with excitation at 250 nm and emission at 395 nm (Figure 2) and by 
comparison to an authenticated synthetic BMAA standard (P. Nunn, Univ. of Portsmouth, UK).  
 
4b2. Fluorescence HPLC methods for analysis of total BMAA  
 
CMMED-01 was hydrolyzed (63 mg/mL wet weight) in 6 N HCl (400 μL) for 16 hours at 110ΕC. 
The hydrolysate (200 μL) was filtered at 13,800 g for 3 min (0.22 μm Ultrafree-MC, Millipore). The 
residue was dried down using a speed vacuum (Thermo-Savant SC250DDA Speed Vac Plus, 
Waltham, MA) and resuspended in 20 mM HCl (100 μL).  The sample was diluted 1:10 using 20 mM 
HCl before derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate [sample (20 μL) 
was buffered with 0.5 M borate (80 μL) and derivatized with AQC (20 μL)]. Sample batch included 
blanks [20 mM HCl (20 μL) with 0.5 M borate (80 μL) and derivatized with AQC (20 μL)], 
derivatized 17 amino acid standard complex (Pierce #NCI0180, Rockford, IL) with a BMAA spike to 
assure adequate separation, derivatized BMAA standard for quantification, HPLC grade water blanks, 
derivatized low-level spiked samples for peak identification and to check for a balanced reaction, a Mar. Drugs 2007, 5  191  
 
matrix blank of hydrolyzed, derivatized Lycopersicon esculentum Mill. (Solanaceae) for a negative 
control, a matrix blank of hydrolyzed, derivatized L. esculentum spiked with low-levels of BMAA and 
a blank of derivatized L-2,4-diamino-n-butyric acid which has a molecular weight of 118.13, 
equivalent to BMAA but with a different structure.  
BMAA was separated from other amino acids by reverse-phase elution (Waters Nova-Pak C18 
column, 3.9 x 300 mm) on a Waters 1525 binary HPLC pump and a Waters 717 Autosampler using a 
gradient method with 140 mM sodium acetate, 5.6 mM triethylamine, pH 5.7 (Eluent A), and 52% 
acetonitrile in water (Eluent B) at 37°C, a flow rate of 1.0 mL/min, and a 20 μL sample injection. The 
standard amino acid elution gradient was modified for BMAA separation on a 30 min gradient (0.0 
min = 75% A; 2.0 min = 75% A curve 6; 17.0 min = 63% A curve 7; 18.5 min = 100% B curve 6; 23.5 
min = 100% B curve 6; 25.0 min = 75% A curve 6; 30.0 min = 75% A curve 6). BMAA concentration 
was quantified by detection of the fluorescent tag (Waters 2475 Multi λ-Fluorescence Detector) with 
excitation at 250 nm and emission at 395 nm (fig. 3) and by comparison to an authenticated synthetic 
BMAA standard (P. Nunn).            
 
4c. UPLC-UV Methods for quantification of total BMAA in CMMED-01 
 
Methods for quantification of BMAA were adapted from previously validated High Performance 
Liquid Chromatography (HPLC) methods [11] which were transferred and optimized to Ultra 
Performance Liquid Chromatography (UPLC7). Waters Acquity UPLC methods for amino acid 
analysis with ultraviolet (UV) detection were used with a modified solvent gradient and validated in 
compliance with United States Pharmacopeia General Chapter 1225 [31]. Eluents were purchased 
from Waters (Eluent A: part #186003838, Eluent B: part # 186003839); composition is proprietary. 
Separation was by reverse phase over 9.5 minutes on a Waters AccQTag Ultra column (part# 
186003837, 2.1x100 mm) at 55°C with a flow rate of 0.7 mL/min  (0.0 min = 0.1% B; 0.54 min = 
0.1% B curve 6; 6.24 min = 9.1% B curve 7; 7.74 min = 21.2% B curve 6; 8.04 min = 59.6% B curve 
6; 8.73 min= 0.1% B curve 6; 9.5 min = 0.1% B curve 6).  
Validation was completed using a BMAA standard (synthesized standard P. Nunn) derivatized 
with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. Ruggedness was evaluated by calculating 
the precision of biweekly triplicate injections at one concentration over 32 weeks (RSD 3.6%). 
Linearity was evaluated by plotting peak area as a function of analyte concentration based on 9 
injections from each of 21 different preparations and regression analysis was performed: slope = 5589; 
intercept = -3198; correlation coefficient = 0.9998; residual sum of squares = 1291469639. The limit 
of detection (LOD) and limit of quantification (LOQ) were determined as 0.1 pmol and 1.1 pmol 
respectively, with a linear range to 539 pmol per injection.  Accuracy (recovery = 98%) was calculated 
by spiking negative control matrix, Lycopersicon esculentum, with known amounts of BMAA in 
triplicate at five concentrations. Precision was evaluated with two measures, repeatability and 
intermediate precision. Repeatability was assessed with triplicate injections at five concentrations on 
two consecutive days (RSD 1.2%). Intermediate precision was calculated biweekly over 32 weeks with 
triplicate injections at three concentrations (RSD 3.9%).  Selectivity was verified with in-line LC/MS 
as noted below. 
Methods for sample preparation were adapted from validated HPLC methods [11]. Twenty mg of Mar. Drugs 2007, 5  192  
 
freeze dried cells from cultured CMMED-01 were weighed in triplicate and hydrolyzed in 6 M HCl 
(400 μL) at 110°C for 16 hours. Hydrolysate (200 μL) was filtered with a 0.22 μm centrifugal filter 
device (Millipore Ultrafree-MC), dried to completeness, then suspended in 20 mM HCl (100 μL) and 
diluted 1:10. Sample (20 μL) was buffered with 0.5 M borate (80 μL) and derivatized with Waters 
AccQTag reagent (20 μL); 2 μL were injected. BMAA in the cyanobacterial samples was quantified 
using the validated UPLC method above, with UV detection at 260 nm. Sample batch included blanks 
[20 mM HCl (20 μL) with 0.5 M borate (80 μL) and derivatized with AQC (20 μL)], derivatized 17 
amino acid standard complex (Pierce #NCI0180, Rockford, IL) spiked and unspiked with BMAA to 
assure adequate separation, derivatized BMAA standard for quantification, derivatized low-level 
spiked samples for peak identification and to check for a balanced reaction, a negative matrix blank of 
hyrdolyzed Homolanthus nutans Muell. Arg. (Euphorbiaceace), and a matrix blank of hydrolyzed H. 
nutans spiked with low-levels of BMAA. The presence of the non-protein amino acid BMAA as well 
as some of the 20 essential protein amino acids were determined by reference to synthetic BMAA and 
a multiple amino acid standard (Pierce #NCI0180, Rockford, IL.; Figures 4, 5). 
 
4d. Amino Acid Analyzer methods for CCMED-01 
 
Freeze dried CMMED-01 Nostoc was hydrolyzed (63 mg/mL) in 6 N HCl (400 mL) for 16 hours 
at 110°C. The hydrolysate (200 μL) was filtered at 13,800 g for 3 min (0.22 μm Ultrafree-MC, 
Millipore). The residue was dried down using a speed vacuum (Thermo-Savant SC250DDA Speed 
Vac Plus, Waltham, MA) and resuspended in 20 mM HCL (100 μL). The sample was diluted 1:10 
using 20 mM HCl. Underivatized sample (20 μL) was injected into a Hitachi Amino Acid Analyzer 
L8900 equipped with a Hitachi Reaction column (PN 855-3533) at 135°C, a high speed physiological 
fluid analysis analytical column Li-form resin #2622SC 6 mm ID x 40 L 060928C (PN855-4515), 
precolumn (PN855-3643), guard column #2619 4 mm ID x 5 L 2007.07.19 070639 (PN855-5268), and 
AmmoniaFilter column (Ion exchange 4.6 x 40 Column #2650L, PN 855-3523). Hitachi pre-made 
buffers were used as follows: (B1) PF-1/AN0-8711, (B2) PF-2 /AN0-8712, (B3) PF-3/An0-8713, (B4) 
PF-4/An0-8714, (B5) 5% methanol, (B6) PF-RG/An0-8715, (R1) ninhydrin solution, (R2) ninhydrin-
buffer of lithium acetate dihydrate, (R3) 5% ethanol.  Separation was made with a flow rate for pump 1 
of 0.53 mL/min and 0.45 mL/min for pump 2 and a 152 min gradient elution (0.0 min = 100% B1, 
separation column and guard column temp 35°C, 50% R1, 50% R2; 1.5 min = column 32°C; 15.6 min 
= 81% B1, 19% B2, column 57°C; 36 min = 60°C; 45 min = 32°C; 57 min = 70°C; 68 min = 15% B1, 
75% B2, 10% B3; 69 min = 58°C; 76.1 min = 60% B2, 40% B3; 89 min = 65°C; 95 min = 20% B2, 
80% B4; 98.1 min= 25% B2, 75% B4; 112.1 min = 100% B4; 125 min = 70°C; 125.1 min = 100% R3; 
129.1 min = 100% B6; 132.1 = 100%B1; 137.1 min = 50% R1, 50% R2, 35°C). The presence of 
BMAA was verified by reference to an authenticated synthetic standard (P. Nunn), and a multiple 
amino acid standard (Pierce #NCI0180, Rockford, IL, fig. 6). Sample batches included the following 
underivatized samples: amino acid standards with and without BMAA spikes, BMAA, L-2,4-diamino-
n-butyric acid, which has a molecular weight of 118.13 equivalent to BMAA, hydrolyzed 
Lycopersicon esculentum, o-methyl-L-tyrosine,  L-o-methylthreonine,  s-methyl-L-cysteine,  n-ε-
methyllysine HCl, L-2,3,diaminoproprionic acid HCl, N
t-methyl-L-histidine, methylamine HcC, 3 
methyl-L-histidine, N
G-methyl-l-arginine and amino acid standard physiological basic A6282 (Sigma).   Mar. Drugs 2007, 5  193  
 
4e. LC/MS methods for verification of presence of BMAA in CMMED-01 
 
A CMMED-01 Nostoc sample prepared as in 2a was injected (5 μL) into a Waters UPLC on a 
Waters AccQTag Ultra column (part# 186003837, 2.1x100 mm) at 55°C with a flow rate of 0.7 
mL/min, using the UPLC method previously noted. A post-column split of the flow delivered a flow 
rate of 0.3 mL/min to a Waters EMD 1000 single quadrupole mass spectrometer. Nitrogen gas was 
purified to 99.2% using a NitroFlow nitrogen generator (Parker Balston, Haverfill, MA) and supplied 
to the electrospray ionization interface at 116 psi with desolvation at 500 L/hr. Positive ion mode was 
used to detect BMAA derivatized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) 
(Waters AccQTag reagent, part # WAT052880), using single ion monitoring at 459.20 Daltons with a 
span of 0.3 Daltons and a dwell time of 0.5 seconds. The source temperature and desolvation 
temperature were 130°C and 300°C respectively.  Voltages were as follows: capillary 3.05 kV, cone 
27 V, extractor 1 V, RF lens 0.4 V. LC/MS verification of the UPLC peak (Figure 5) was obtained 
(Figure 6), as were LC/MS verifications of AQC derivatized CMMED-01 samples spiked with 11 
picomoles  and 22 picomoles BMAA respectively (Figure 7).  Sample batch included blanks [20 mM 
HCl (20 μL) with 0.5 M borate (80 μL) and derivatized with AQC (20 μL)], derivatized 17 amino acid 
standard complex (Pierce #NCI0180, Rockford, IL) spiked with BMAA to assure adequate separation, 
derivatized BMAA standard for quantification, and derivatized low-level spiked samples for peak 
identification and to check for a balanced reaction and a negative matrix blank of hyrdolyzed 
Lycopersicon esculentum Mill. (Solanaceae), a matrix blank of hydrolyzed L. esculentum spiked with 
low-levels of BMAA, and a blank of L-2,4-diamino-n-butyric acid which has a molecular weight of 
118.13 equivalent to BMAA but with a different structure. 
 
4f. Triple Quadrupole LC/MS/MS 
 
Identification of a BMAA peak in a marine Nostoc CMMED-001 sample was verified by liquid 
chromatography/mass spectroscopy/mass spectroscopy (LC/MS/MS) using product ion mode in a 
triple quadrupole system. The freeze-dried cyanobacteria sample was hydrolyzed for 18 hours in 6 N 
HCl at 110°C and then dried to remove HCl in a Thermo-Savant SC250DDA Speed Vac Plus 
(Waltham, MA). The sample was reconstituted in dilute HCl (20 mM) and derivatized with AQC, 
which increased the molecular weight of the BMAA analyte from 118 to 458. To increase the quantity 
of analyte injected into the LC/MS/MS, the BMAA peak was collected three times from a Waters 1525 
binary HPLC pump and a Waters 717 Autosampler, with separation through a Waters 3.9 x 300 mm 
Nova-Pak C18, 4 μm column (Lot No.: 11143603410254) at 37°C.  Individual compounds were eluted 
from the column with a gradient elution of 140 mM sodium acetate buffer, 5.6 mM triethylamine, pH 
5.7 (mobile phase A) and 52% acetonitrile (mobile phase B) with a flow rate of 1.0 mL/min. The 
collected peaks were dried to reduce the volume in a Thermo-Savant SC250DDA Speed Vac Plus with 
a Savant refrigerator trap RVT 4104. The first collected peak was then reconstituted in HPLC grade 
water (50 mL), heated to 55°C, vortexed, and then added to the second and third peak iteratively which 
were likewise heated and vortexed in a similar fashion. The concentrated filtrate was injected into a 
triple quadrupole system (Thermo model TSQ Quantum Discovery Max, San Jose, CA). Separation 
was achieved by liquid chromatography (Thermo model Surveyor LC, San Jose, CA) utilizing a Mar. Drugs 2007, 5  194  
 
Thermo Hypersil GOLD 100 x 2.1 mm, 3 μm column at 0.28 mL/min, 0.1% formic acid in water 
(Eluent A), 0.1% formic acid in acetonitrile (Eluent B) gradient elution (0.0 min = 100% A; 2 min = 
100% A; 16 min = 80% A; 20 min = 2% A; 22 min = 2% A; 24 min = 81% B; 26 min = 81% A; 27 
min = 100% A; 31 min =100% A). Nitrogen gas was supplied to the H-ESI probe (heated electrospray 
ionization) with a nebulizing pressure of 25 psi and a vaporizing temperature of 300°C. The mass 
spectrometer was operated under the following conditions: the capillary temperature was set at 280°C, 
capillary offset of 35, tube lens offset of 94, source collision energy of 5, and multiplier voltage of -
1194. The second quadrupole was pressurized to 1.5 mTorr with 100% Argon.  
The derivatized molecule after ionization (MW 459) via HESI was selected as the precursor ion for 
analysis. Collision induced dissociation (CID) was achieved in the second quadrupole using the 
following parameters:  459 → 119 CE 19; 459 → 171 CE 32; and 459 → 289 CE 16. The resultant 
three product ions of the derivatized BMAA (MW 119, 289, 171) were scanned by the third 
quadrupole, subsequently detected, and their relative abundances quantified. The ratios of these three 
product ions were compared to the ratios of the product ions created by injection of AQC-derivatized 
ultra pure, triple crystallized BMAA standard (Peter Nunn) into the mass spectrometer under the same 
conditions (Figure 9). Sample batch included blanks (20 μL of 20 mM HCl with 80 μL 0.5 M borate 
and derivatized with 20 μL AQC), derivatized 17 amino acid standard complex (Pierce #NCI0180, 
Rockford, IL) to assure adequate separation, derivatized BMAA standard for quantification, HPLC 
grade water blanks, derivatized norleucine blanks, and a blank of L-2,4-diamino-n-butyric acid which 
has a molecular weight of 118.13, equivalent to BMAA but with a different structure, retention time, 
and product ions. 
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